|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 高剂量美罗培南与多黏菌素B的联合:解决鲍曼不动杆菌碳青霉烯类耐药性问题的新策略显示文摘长期以来,多黏菌素与碳青霉烯类药物联合用于治疗碳青霉烯类耐药鲍曼不动杆菌的药效学研究较少。作者对多黏菌素B与高剂量美罗培南联合使用是否可以提高杀菌率以及抑制对碳青霉烯类耐药的产生进行了研究。 | 卞星晨 刘笑芬 Lenhard JR Bulitta JB Terry D | 2017 | 中国感染与化疗杂志2017，17，4： | 8 |
| 2 | Penetration of antibacterials into bone pharmacokinetic,pharmacodynamic and bioanalytical considerations显示文摘 | Landersdorfer CB Bulitta JB Kinzig M | 2009 | Clin Pharmacok2009，48，2： | 1 |
| 3 | Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus(MRSA):implications for dosing in MRSA pneumonia显示文摘 | Harigaya Y Bulitta JB Forrest A | 2009 | Antirmicrob Agents Chemother2009，53，9： | 1 |
| 4 | Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosaat multiple inocula显示文摘 | Bergen PJ Forrest A Bulitta JB | 2011 | Antimicrob Agents Chemother2011，55，11： | 1 |
| 5 | Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations显示文摘 | Tsuji BT Bulitta JB Brown T | | J Antimicrob Chemother 20 12 90，67，9： | 1 |
| 6 | Disposition,oral bioavailability,and tissue distribution of zearalenone in rats at various dose levels显示文摘 | Shin BS Hong SH Bulitta JB | 2009 | J Toxical Environ Health A2009，72，2122： | 1 |
| 7 | Nonlinear pharmacokinetics of piperacillin in healthy volunteersimplications for optimal dosage regimens显示文摘 | Bulitta JB Kinzig M Jakob V | | 0，，： | 1 |
| 8 | Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against muhidrug-resistant Pseudomonas aeruginosa at multiple inocula显示文摘 | Bergen PJ Forrest A Bulitta JB | 2011 | Antimicrob Agents Chemother2011，55，11： | 1 |
| 9 | Pharmacokinetics of ertapenem in colorectal tissue显示文摘 | Wittau M Scheele J Bulitta JB | | 0，，： | 1 |
| 10 | Synergistic killing of mul- tidrug-resistant Pseudomonas aeruginosa at multiple inocula by co- listin combined with doripenem in an in vitro pharmacokinetic/ pharmacodynamic model 显示文摘 | Bergen PJ Tsuji BT Bulitta JB | 2011 | Antimicrob Agents Chemother2011，55，12： | 1 |
| 11 | Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipencm-cilastatin in critically ill patients in a randomized, controlled trial显示文摘 | Sakka SG Glauner AK Bulitta JB | 2007 | Antimicrob Agents Chemother2007，51，9： | 1 |
| 12 | Pharmacokinetic/ pharmacodynamic investigation of colistin against pseudomonas aeruginosa using an in vitro model 显示文摘 | Bergen P J Bulitta JB Forrest A | 2010 | Antimicrob Agents Chemother2010，54，： | 1 |
| 13 | Phase 2,randomized,double-blind,dose-ranging study evaluating the safety,tolerability,population pharmacokinetics,and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections显示文摘 | Prokocimer P Bien P Surber J Mehra P DeAnda C Bulitta JB Corey GR | 2011 | Antimicrob Agents Chemother2011，55，2： | 1 |
| 14 | Combination therapy for carbapenem resistant gram-negative bacteria显示文摘 | Zavascki AP Bulitta JB Landersdorfer CB | 2013 | Anti Infect Ther2013，11，12： | 1 |
| 15 | Application of pharmacokinetic-pharmacodynamic modeling and the justifica- tion of a novel fusidic acid dosing regimen: raising Lazarus from the dead显示文摘 | Tsuji BT1 Okusanya OO Bulitta JB | 2011 | Clin Infect Dis2011，，： | 1 |
| 16 | Penetration of antibac- terials into bone: pharmacokinetic, pharmacodynamic and bioanalyt- ical considerations 显示文摘 | Landersdorfer CB Bulitta JB Kinzig M | 2009 | Clin Pharmacokinet2009，48，2： | 1 |
| 17 | Combination therapy for carbapenem-resistant Gram-negative bacteria 显示文摘 | Zavascki AP Bulitta JB Landersdorfer CB | 2013 | Expert Rev Anti Infect Ther2013，11，12： | 1 |
| 18 | Evaluation of the pharmacokinctics-pharmacodynamics of fusidic acid against Staphylococcus attreus and Streptococcus pyogenes using in vitro infection models: implications for dose selection显示文摘 | Okusanya OO Tsuji BT Bulitta JB | 2011 | Diagn Micro- biol Infect Dis2011，70，1： | 1 |
| 19 | Combination therapy for carbapenem-resistant Gram-negative bacteria显示文摘 | ZAVASCKI AP BULITTA JB LANDERSDORFER CB | 2013 | Expert Rev Anti Infect Ther2013，11，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员